Rapid communication Open Access
Like 0


Functional immunity (defined here as serum neutralising capacity) critically contributes to conferring protection against SARS-CoV-2 infection and severe COVID-19. This cross-sectional analysis of a prospective, population-based cohort study included 1,894 randomly-selected 16 to 99-year-old participants from two Swiss cantons in March 2022. Of these, 97.6% (95% CI: 96.8–98.2%) had anti-spike IgG antibodies, and neutralising capacity was respectively observed for 94%, 92% and 88% against wild-type SARS-CoV-2, Delta and Omicron variants. Studying functional immunity to inform and monitor vaccination campaigns is crucial.


Article metrics loading...

Loading full text...

Full text loading...



  1. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326(20):2043-54.  https://doi.org/10.1001/jama.2021.19499  PMID: 34734975 
  2. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021;385(24):e84.  https://doi.org/10.1056/NEJMoa2114583  PMID: 34614326 
  3. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022;386(13):1207-20.  https://doi.org/10.1056/NEJMoa2118691  PMID: 35172051 
  4. Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, et al. , DMID 21-0012 Study Group. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022;3(7):100679.  https://doi.org/10.1016/j.xcrm.2022.100679  PMID: 35798000 
  5. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol. 2022;94(7):2969-76.  https://doi.org/10.1002/jmv.27697  PMID: 35246846 
  6. West EA, Anker D, Amati R, Richard A, Wisniak A, Butty A, et al. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. Int J Public Health. 2020;65(9):1529-48.  https://doi.org/10.1007/s00038-020-01494-0  PMID: 33098441 
  7. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.  https://doi.org/10.1016/j.jbi.2008.08.010  PMID: 18929686 
  8. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.  https://doi.org/10.1016/j.jbi.2019.103208  PMID: 31078660 
  9. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. 2021;95(3):e01828-20.  https://doi.org/10.1128/JVI.01828-20  PMID: 33144321 
  10. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-9.  https://doi.org/10.1016/S0140-6736(20)31304-0  PMID: 32534626 
  11. Fenwick C, Turelli P, Pellaton C, Farina A, Campos J, Raclot C, et al. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci Transl Med. 2021;13(605):eabi8452.  https://doi.org/10.1126/scitranslmed.abi8452  PMID: 34257144 
  12. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. OurWorldInData.org. [Accessed 18 May 2022]. Available from: https://ourworldindata.org/covid-hospitalizations#licence.
  13. European Centre for Disease Prevention and Control (ECDC). Data on hospital and ICU admission rates and current occupancy for COVID-19. Stockholm: ECDC; Jul 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/download-data-hospital-and-icu-admission-rates-and-current-occupancy-covid-19
  14. Office for National Statistics (ONS). Coronavirus (COVID-19) latest insights: Antibodies 2022. Newport: ONS; Jul 2022. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/antibodies
  15. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill. 2021;26(27):2100568.  https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100568  PMID: 34240697 
  16. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-11.  https://doi.org/10.1038/s41591-021-01377-8  PMID: 34002089 
  17. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(17):606-8.  https://doi.org/10.15585/mmwr.mm7117e3  PMID: 35482574 
  18. Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, et al. increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: An update from the COV-AD Study. Front Immunol. 2022;13:912571. PMID: 35720400 
  19. Aziz NA, Corman VM, Echterhoff AKC, Müller MA, Richter A, Schmandke A, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun. 2021;12(1):2117.  https://doi.org/10.1038/s41467-021-22351-5  PMID: 33837204 
  20. Topol EJ, Iwasaki A. Operation Nasal Vaccine—Lightning speed to counter COVID-19. American Association for the Advancement of Science; 2022. p. eadd9947.

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error